3. Duplicative Therapy

Printer-friendly version

There are no FDA indications for duplicate therapy with multiple combination drug products (e.g. ledipasvir/ sofosbuvir (Harvoni®) with glecaprevir/pibrentasvir (Mavyret™))^2-11.

Ribavirin combination therapy is indicated in patients with more advanced liver disease and HCV genotypes that are found to be more resistant (e.g. genotype 3)^1,11.

For recommended combination therapies see Duration of Therapy tables above (Tables 1-3).